Clinical Trial for evaluation of the clinical effect of on line hemodiafiltration (HDF) and beta2-microglobulin adsorption column combination therapy.

Clinical Trial for evaluation of the clinical effect of on line hemodiafiltration (HDF) and beta2-microglobulin adsorption column combination therapy. - Clinical Trial for evaluation of the clinical effect of on line hemodiafiltration (HDF) and beta2-microglobulin adsorption column combination therapy.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000009429

Enrollment

Registered

2012-11-29

Start date

2012-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

dialysis-related amyloidosis

Interventions

Change from hemodialysis (HD) to on line HDF (1st phase: for 4 months) Combine on line HDF and beta2-microglobulin adsorption column. (2nd phase: for 4 months) Return from on line HDF and beta2-mi

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1)Patients who has initiated hemodialysis before more than 10 years. (2)Patients with dialysis-related amyloidosis or similar symptoms.

Exclusion criteria

Exclusion criteria: Nothing

Design outcomes

Primary

Measure	Time frame
Improvement of clinical symptoms, circulatory dynamics, and nutritional and inflammatory status.	—

Countries

Japan

Contacts

Public ContactTakahiro Kuragano

Hyogo College of Medicine Division of Kidney and Dialysis, Department of Internal Medicine

kuragano@hyo-med.ac.jp0798-45-6521

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026